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ABSTRACT
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Kenneth E. Ike, Alan Morrison, and Jeffrey R. Bender. Section of Cardiovascular
Medicine, Department of Internal Medicine, Yale University, School of Medicine, New
Haven, CT.
HMG-CoA reductase inhibitors (statins) are pharmaceuticals that are utilized for the
treatment of lipid disorders along with the primary and secondary prevention of coronary
heart disease. HMG-CoA reductase is the rate-limiting enzyme in cholesterol synthesis,
converting HMG-CoA to mevalonate. The isoprenoid products, farnesyl pyrophosphate
(FPP) and geranylgeranyl pyrophosphate (GGPP), are derived from the mevalonate
pathway and serve as substrates in the prenylation of 2% of cellular proteins including the
Rho family of low molecular weight G-proteins which mediate multiple cellular signals.
Prenylation is an important post-translational modification of proteins that plays a role in
the subcellular localization of proteins to certain hydrophobic (membrane) compartments.
This localization can affect overall protein function. We demonstrate that manipulation of
the prenylation state of Rac2 alters the formation of a signaling complex between Rac2
and Myosin IIA that forms via !2 integrin engagement coupled to chemokine (CCL2,
MCP-1) stimulation. This complex appears critical to the translocation of the RNA
binding protein, HuR, from the nucleus to the cytosol whereby it functions to exact its
effects on mRNA stability. HuR translocation prolongs the half-life of transcripts
encoding critical inflammatory, immune and angiogenic cytokines like TNF-", INF-#,
and VEGF-A. This pathway may represent a pleiotropic effect of statin therapy and may
serve as a target for future small molecule therapeutics with anti-inflammatory potential.
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INTRODUCTION
Pleiotropic Effects of Statins
Strictly defined, pleiotropy is the phenomena where a single gene has multiple
phenotypic effects. The same process can be and has been applied to pharmacologic
agents, like statins. It is well recognized that the targeted effect of statins, or HMG-CoA
reductases, is the inhibition of cholesterol synthesis downstream of mevalonate.
However, in addition to the well-characterized lipid lowering effects, multiple beneficial
off-target effects have been established over the last 25 years of clinical experience.
Examples to be reviewed here include actions on endothelial cells, antioxidant effects,
effects directly on leukocytes, effects on plaque stability, anti and pro-angiogenic effects,
and effects directly on the cardiac myocardium (1).

The effect of statins on endothelial cell function has been linked to the direct effects
statins have on endothelial nitric oxide synthase (eNOS) activity, subsequent NO
production and inhibition of endothelin-1 (ET-1) synthesis (2). In regards to eNOS
activity, there have been numerous studies supporting that statins increase mRNA
stability of eNOS providing protection during times of vascular insult which include
conditions of hypoxia, increased ox-LDL, and elevated IL-1 and TNF-! levels (3).
Statins, particularly atorvastatin, have also been shown to inhibit the production of a
protein named caveolin-1 (4). Caveolin-1 is a potent inhibitor of eNOS activity. Statins
inhibit the formation of a caveolin-1 complex that inhibits eNOS by modulating its
expression.
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By both in vivo and in vitro studies, statins have antioxidant activity by decreasing the
amount of reactive oxygen species (ROS). The mechanism involves the inhibition of p21
Rac isoprenylation, which affects its key functional role the NADPH oxidase system of
endothelial cells and reduces the production of ROS (5).

There is evidence to support the hypothesis that statins exert a direct inhibition of
leukocyte activation. Though the mechanism of this inhibition is not clear, there are
several possibilities for how this might occur. First, statins directly reduce the expression
of adhesions molecules, particularly intracellular adhesion molecule -1 (ICAM-1) on
endothelial cells (6). ICAM-1 is critical for the adhesion, activation, and transendothelial
migration of the leukocyte from the vasculature. Further, it is known that integrin
adhesion is dependent on small GTPase Rho activation (7). The dependence of Rho
activation on isoprenylation provides a potential interventional site for statins. Finally,
certain statins, including lovastatin and simvastatin, directly inhibit leukocyte endothelial
binding through a specific binding site on expressed adhesion molecules such as LFA-1
(8). The significance of these effects may be a crucial part of the non-lipid lowering
contributions to beneficial cardiovascular outcomes. This thesis will attempt to expand on
the function of a small G-protein that further elucidates this premise.

Statins have been shown to have multifaceted effects that promote plaque stability. One
important mechanism of statins is the ability to decrease scavenger receptor expression
and ox-LDL uptake by macrophages (9). A decrease in ox-LDL uptake reduces foam cell
formation, which is a key determinant of plaque stability. Another key effect of statins is
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that they inhibit the macrophage ability to migrate in plaque and produce matrix
metalloproteinases (MMP), which are necessary for the degradation of extracellular
matrix (10). The net effect of MMP modulation on plaque stability is still debated but
provides another avenue for explanation of the statin contribution to plaque instability.

Statins may be involved in numerous aspects of angiogenesis in a dose dependent
manner, although the exact role of statins in angiogenesis is debated (11). Statins have
been implicated in the mobilization and maturation of endothelial progenitor cells
(EPC’s), which are important in contributing to endothelial regeneration at sites of
vascular stress. Risk factors like hypertension, hypercholesterolemia, and diabetes are
associated with decreased levels of EPC’s. Statin therapy appears to counteract this effect
(12).

The role of vascular endothelial growth factor (VEGF) is interesting and controversial.
VEGF is known to have positive effects on vascular remodeling, but prior studies
demonstrate that statins decrease the plasma concentration of VEGF (13). This is a
seemingly paradoxical effect when considering factors in cardiovascular mortality and
morbidity. Studies done in apolipoproteinE/ apolipoprotein B-100 mice with different
statin types may begin to shed light on this paradox.

Moving from animal models to the clinic, there are numerous trials that have established
the vascular and cardio protective effect of statins particularly in regards to acute
coronary syndrome (ACS). One such study, the PROVE IT –TIMI 22 trial, randomized
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4162 patients to either pravastatin or atorvastatin and found a 28% reduced risk in
composite death, MI or rehospitalization for recurrent ACS for subjects in the statin
treatment group (14). The Justification for the Use of Statins in Primary Prevention: An
Intervention Trial Evaluating Rosuvastatin (or Jupiter) trial examined people with
elevated CRP levels, as a marker for inflammatory state, but relatively normal lipid
levels, and determined that people who took statins has a 40% relative risk reduction for
heart attack, stroke and death after 1 year (15). This study raises further questions about
the role inflammation has in cardiac and vascular disease.

Characterization and Functional Role of Rac2 in Cell Signaling
Rac2 is part of the Rho subfamily small GTPases (16). There are six subfamilies that
include the RhoA-related subfamily (RhoA, RhoB, RhoC), the Rac1-related subfamily
(Rac1, Rac2, Rac3, and RhoG), the CDC42 related subfamily (CDC42, g25k, tc10, tcl,
chp/wrch-2 and wrch-1) the RnD subfamily (Rnd1, Rnd2, and RhoE/Rnd3), the RhoBTB
subfamily and the Miro subfamily (17). Specifically in the Rac1 subfamily, 88%
homology of sequence is shared between Rac1, 2, and 3 with major differences lying in
their C-terminal residues. Traditionally, this family of proteins is thought to share similar
functions as molecular switches with two forms that predominate; a GTP-bound (active)
and a GDP-bound (inactive). The transition between GTP to GDP bound states of the
GTPase is regulated by two groups of proteins. One group is called the guanosine
nucleotide exchange factors or (GEF’s) which serve to bind the GTPases with GTP. This
group has a Dbl - homology (DH) domain responsible for catalytic activity and a
pleckstrin homology (PH) domain responsible for membrane or lipid localization. The
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second groups of regulators are labeled GTPase-activating proteins (GAP’s) and serve to
switch GTP for GDP on the GTPases. The active form of the GTPases and including
Rac2 are thought to play a role in a variety of cellular processes including cellular
proliferation, NADPH oxidase activity, gene expression, cell adhesion, and cell motility
(18).

There are other proteins that may have intimate roles in the functional regulation of these
proteins. One such protein is RhoGDI. There are three Rho GDI’s, RhoGDI 1, 2, 3 or
alpha, beta, gamma. RhoGDI 2 is LyGDI or D4GDI. These are regulatory proteins
known to interact with Rho GTPases and regulate the localization of the Rho GTPases
between cytosol and membrane (19). In addition they have domains that regulate the
GTP/GDP cycling function carried out by Rho GTPases that is handled in their switch
regions. Proteins in the GDI family make a variety of contacts with members of the Rho
small GTPase class and may be involved in regulatory processes to varying degrees
based on cell type and small GTPase variant.

In addition to the switch regions that regulate GTP-GDP association and the contact
points for the GDI proteins, the small GTPases have a prenylation modification that
consists of isoprenoid products derived from the mevalonate pathway (20). Prenylation is
an important post-translational modification of proteins that often plays a role subcellular
localization of proteins to certain hydrophobic compartments (21). The prenylation type
is determined by the 4th cysteine residue position from the C terminus (COOH) of the Gprotein, containing a CAAX (C-Cysteine, A-Aliphatic, X- serine, methionine, glutamine,
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alanine or threonine) motif sequence (22). The sequence will determine whether one of
two prenylation groups, farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate
(GGPP), will be added by a farnesylation (by fransyltransferase) or a geranylgeranylation
(by geranylgeranyl transferase) reaction. Rac2 posses a CSLL sequence which signals a
geranylgeranylation by the action of geranylgeranyl transferase I (23). This modification
allows Rac 2, to remain soluble in the cytosol and associated with the GDI (Guanine
dissociation inhibitor) or to move to the plasma membrane to mediate downstream
signaling events (18). Multiple crystal structures of various members of the different
GTPase families have shown interaction with the GDI molecule (24).

Rac2 and other members of the small GTPase protein family have been linked to
numerous effector proteins. A common theme among these interactions is that residues in
the switch I region of the proteins are key for guiding reactions with different effector
cells. For example, Rac’s interaction with p21 activated kinase (PAK) is dependent on a
tyrosine residue at the 40th position, but another residue position determines its
interactions with mixed lineage kinase (Mlk 2 and 3). In addition to PAK and Mlk, Rac
interactions have been linked to Ser/Thr kinases, PI-4-P5K, POR-1, PLD, PI3K, DAG
kinase, PLC-B2, Wave/Scar, POSH, p67 phox, IQGAP and among others that affect a
variety of pathways (25). These pathways include interactions with actin, SRF, JNK/p38,
NF-kB, NADPH oxidase system, cell-cell contacts and cell cycle progression. The
mechanism by which the small GTPases, particularly, Rac function to activate the
effector proteins is through disruption of intramolecular auto-inhibitory domains that
regulate kinase activity. Upon binding to Rac, the inhibitory domain unfolds and becomes
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exposed allowing kinase activity to ensue.

Macrophage Role in development of Vascular Disease
Monocytes are a uniquely positioned cell type in the inflammation pathway. Their
regulation depends partly on the activity of small GTPases that are expressed
intercellularly. In addition, they play a pivotal role in driving the inflammatory response
involving plaque deposition in the vasculature. Monocytes interact with adhesion
molecules that are expressed on the surface of endothelial cells in response to ox-LDL or
other activators. Chemokines like monocyte chemoattractant protein 1 (MCP-1) have
been implicated in the migration of the monocyte into the intima layer of the vessel wall
and also drive the maturation of monocytes to macrophages (26). The maturation and
activation of the monocyte depends partly on those chemokines, and others like
macrophage colony stimulating factor (M-CSF) help to drive the expression of
scavengers’ receptors on the macrophage and allow for the consumption of ox-LDL
molecules by the macrophage. The ox-LDL is believed to bind to CD-36 and lead to
further activation of the macrophage within the plaque (27). This activation state leads to
the expression of many other inflammatory cytokines that in turn effect endothelial cells,
smooth muscle cells, lymphocytes, and other macrophages. Consequently, this further
drives the inflammatory environment and the pathology of the plaque. The structural
integrity of the plaque is challenged by increased expression of matrix metalloproteinases
(MMP’s) and by macrophages that degrade the components of the extracellular
scaffolding. This is important because plaque stability plays an important role in rates of
spontaneous plaque rupture and downstream consequences.
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There is evidence that supports the significance of the different subsets of macrophages
in the progression of atherosclerotic plague. The two subtypes of macrophages include
M1 and M2. The M1 subtype is pro-inflammatory and expresses cytokines that include
IL-1", TNF and IL-6. The M2 subtype has a high expression of scavenger receptors and
might be expected to phagocytize lipid. The distinction of macrophage phenotype
supports the timeline seen in the ApoE knockout mouse model. In the ApoE model of
atherosclerotic plaque development, histologic examination of vessel walls demonstrates
that early in atherosclerotic plaque progression the M2 subtype macrophage predominates
in lesions whereas the M1 subtype dominates in the later phases (28).
Role of Chemokines in development of Atherosclerotic Plaque
Several chemokine/chemokine receptor pairings have numerous studies in mice that show
independent and additive effects on their ability to reduce the atherosclerotic burden.
Mouse models seem to stratify the influence of the three chemokine/chemokine receptors
into 3 major events. The first phase is macrophage recruitment, which has been linked
primarily with CCL5, mediated stimulation of CCR5. The second phase is early
monocyte adhesion, which has been shown to be mediated by the CCL2/CCR2
interaction. The third phase is chronic monocyte adhesion, which has been shown to be
supported by the fractalkine/CX3XR1 interaction (29).

Monocyte chemoattractant protein 1 (MCP-1), also known as CCL2, is a key chemokine
that promotes the migration of monocytes/macrophages. This chemokine is part of the
CC subgroup of chemokines, is roughly 13 kDa in size, and the gene is located on
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chromosome 17q11.2. MCP-1 works by binding to chemokine receptors CCR2 and
CCR11. CCR2 is a G-protein coupled receptor located on the surface of inflammatory
cells. Binding to CCR2 results in the formation of IP3, activation of PKC, and release of
intracellular calcium stores. CCR11 actions are less well described. The intracellular
pathways of MCP1 signaling involve numerous downstream effector proteins that
culminate in modulating cell activation and trafficking (26).

During times of inflammatory stress, multiple cell types including endothelial cells,
smooth muscle cells, and monocytes secrete MCP-1 and create a chemotactic
concentration gradient for inflammatory cells to follow. Ox-LDL, but not naïve LDL, has
been shown to induce MCP-1 production by endothelial cells and smooth muscle cells,
which may represent the start of the recruitment of monocytes and the initiation of
atheroma formation.

CX3CL1 (also known as fractalkine) is a member of the CXC subfamily of chemokines.
It is also an important chemokine that plays a role in immune cell trafficking. It consists
of 397 amino acids with 5 unique domains and is encoded on chromosome 16. Its basal
production by endothelial cells and smooth muscle cells is very low, requiring TNF-! for
marked increase. CX3CL binds to CX3CR1, which is another G-protein coupled receptor.
Pro-inflammatory cytokines IL-1", TNF-! and IFN-# which all are implicated in
stimulating an NF-$B pathway that induces expression of CX3CL/CX3CR (30).

CCR5 is a unique chemokine receptor known as a participating receptor that allows HIV
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infection in macrophages and other CCR5 expressing immune cells. The CCR5 gene is
encoded on chromosome 3p21 and responses to ligands CCL3, CCL4, and CCL5 (31).

Characterization, Activation and Role ofβ2 Integrin in Vascular Inflammation
Integrin’s are defined as the cells’ connection between extracellular and intracellular
environments (32). The signaling that occurs in integrin expressing cells is thought to be
directional. When integrins bind, signals are sent from the extracellular domain of the
integrin to the intracellular domains that are associated with cytoskeletal proteins and
other intracellular effectors that act to inform the cell of its present environment. The cell
then reacts via intracellular mechanisms to inform the extracellular component of the
integrin that a change in affinity is needed to direct adhesion or migration. These signal
transduction processes mediated through the integrin molecule are complex. Integrin’s
are composed of many domains and have three prominent conformation states. Each
integrin molecule contains an alpha and beta subunit. Each subunit contains 3 parts that
include an N-terminal extracellular domain, a transmembrane domain and a C-terminal
cytoplasmic domain. There are 18 different alpha subunits that can possibly join with 8
beta subunits for different confirmations. There are two major groups of alpha subunits
within 18 possible subunits. One group contains an !I domain while the other set does
not. This only affects binding with potential ligands by requiring the participation of
different beta subunits or not depending on the alpha subunit group. The key-binding site
for the integrins is the metal ion dependent adhesion sites (MIDAS) whose conformation
is dependent on the conformation of the !I and "I domains. These domains are important
because they drive ligand specificity by driving conformational states that accept only
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certain inflammatory ligands. The alpha subunit is most important in mediating the
binding to particular ligands. In the group of integrins that do not contain the aI domain,
ligand binding is primarily determined by the beta subunit. However, the beta subunit has
the primary function of communicating with the intracellular domains and transmitting
information between components. In terms of the overall conformational states the
integrins have a bent closed, extended closed, and extended open state. Each of these
states differs by the degree to which the ! and " subunit articulate at various extracellular
points particularly at the headpiece region and the hybrid region.
Integrins are important components of the immune effector cell. When the cell is
recruited to a site of inflammation, it must be able to travel out of circulation and localize
itself to specific areas around the precipitating inflammatory event. Part of this process is
aided by the ability of the immune cell to express integrins on the cell surface. Integrins
such as LFA-1 are able to bind to ligands like ICAM-1 that are expressed on a variety of
cell types and help direct the immune response to localized areas. While studying cellcell adhesions in 1986, Springer was able to discern that LFA-1 interacted with other cell
ligands than previously described (33). As part of his investigation of cell-cell adhesions
he was able to determine that when LFA-1 deficient lymphocytes were incubated
together, cell-cell adhesion would not occur in the presence of phorbol ester. However,
when LFA-deficient cells were incubated with normal lymphocytes, adhesion was
present indicating that a ligand other that LFA-1 was necessary for cell-cell adhesion to
take place. Dustin et al further showed that ICAM-1 expression on dermal fibroblasts was
increased three to five times baseline by IL-1 and TNF-alpha (34). More importantly,
they showed that ICAM-1 was expressed on a variety of cell types particularly vascular
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endothelial cells. Springer et al displayed LFA-1 binding to ICAM suspended in an
artificial lipid membrane. These discoveries have led to additional questions regarding
whether or not LFA-1 mediated binding influenced the activation state of the immune
cell.

Members of the Bender lab have contributed significantly to the understanding of the
integrin-mediated processes particularly in T-cells. In 2006, Wang et al. was able to
demonstrate in human peripheral T-cells that engagement of LFA-1 leads to the
prolongation of TNF-a, GM-CSF, IL-3 mRNA half-life and also had an effect on the
mRNA encoding for a chimeric B-globin mRNA reporter construct containing a
destabilizing class II AU-rich element from the GM-CSF mRNA 3’untranslated region
(35). In 2010, Rangolam et al. found in T-cells that LFA-1-induced stabilization of
ARE-containing mRNA’s occurs in T-cells and was dependent on HuR. This involves a
pathway linking Vav-1, Rac1 and 2, MKK3, and p38MAPK proteins (36). In 2012,
Zhang et al. demonstrated that the ICAM – LFA-1 - HuR axis is key for stabilization of
VEGF and MMP-9 labile transcripts in a macrophage model of angiogenesis (37). It is
the role of Rac’s in the integrin induced, HuR-mediated signaling cascade and the
importance of HuR in the macrophage inducible factor production that has led to the
work described in this thesis.

Characterization and Functional Role of Myosin IIA in Cytoskeletal Reorganization
Myosin IIA is classified as a nonmuscle or atypical motor protein that associates with
actin. This association plays a key role in cell migration and adhesion. In terms of
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structure, Myosin IIA has three separate structural domains: globular head, neck region
and rod (38). The first part is a globular head domain that contains regions responsible for
actin binding. This domain also contains an enzymatic Mg+2 ATPase motor domain. The
neck region contains an essential light chain (ELC) and a regulatory light chain (RLC).
The ELC is responsible for stabilization of the heavy chain structure. The RLC is
responsible for overall structure conformation, which is pivotal for actin association. The
coiled coil rod domain allows for dimerization.

On phosphorylation of the RLC, Myosin IIA transforms from a closed 10S assembly to
an open 6S assembly that has an exposed rod domain. This rod domain is then able to
dimerize with the rod domain of other heavy chain assemblies with concomitant actin
interaction with the globular head domain. Studies have shown that there are two residues
on the RLC that are important in terms of regulation. The Ser19 and Thr18 have been
identified as two sites that are integral in promoting Myosin IIA association with actin
through altered baseline conformational changes. Several kinases have been implicated in
RLC phosphorylation including myosin light chain kinase (MLCK), rho associated coiled
coil-containing kinase (ROCK), and CDC42 binding kinase CDC42BP. ROCK also acts
to inhibit protein phosphatase 1 (PP1) which is a key dephosphorylator of Myosin IIA
(39).

Myosin IIA is a key regulator of slow retrograde flow in the lamellum, which is part of
the leading edge of motile cells (39). When Myosin IIA is knocked down or inhibited
with blebbitstatin, actin bundles disappear from the lamellum but not the lamellipodium.
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This finding is key to understanding the overall role for myosin in cell motility. Myosin
IIA also has a role in insuring proper cellular adhesion via its interaction with a variety of
other proteins linked to integrins. In the traditional model, integrins are associated with
actin/myosin clusters via actin linkage proteins that include !-actinin, talin and viniculin.
Interactions between these proteins are important for the activation of a variety of kinases
(focal adhesion kinase, Src, paxillin) that transmit downstream signals through small
GTPase mediated pathways.

In vitro studies involving Rac 1 address this point. Leeuwen et al showed that in the
presence of bradykinin stimulation, Rac1 was activated and regulated the calcium
dependent phosphorylation of MSII in PC12 and N1E-115 cells (40). This
phosphorylation led to increased cell spreading through the reorganization of the
cytoskeletal elements. Notably, this change in phenotype was in contrast to Rho mediated
cell rounding suggesting a possible inhibition of Rho mediated cytoskeletal
reorganization. In terms of releasing contacts made by cell adhesion molecules, the role
of Myosin IIA has also been explored. Morin et al. showed in lymphocytes that
disrupting the interaction of LFA-1 with Myosin IIA resulted in an inability of
lymphocytes to disengage interactions with ICAM-1 at the uropod (41). After inhibition
with blebbistatin or siRNA knockdown, the lymphocytes displayed a more elongated
phenotype and a decreased inability to migrate on ICAM1/CXCL-12 slides compared to
cells in DMSO.
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As mentioned above, blebbistatin, which is a highly specific inhibitor of Myosin IIA was
used in many assays. Blebbistatin is a small molecule, uncompetitive, inhibitor that
preferentially binds to the ADP+P bound form of Myosin IIA at the head region. It does
not interfere with actin myosin binding or ATP induced actin myosin dissociation (42).
Leukocyte HuR Regulation in Integrin induced RNA Stabilization
Human antigen R or HuR is an RNA binding protein that is a member of the embryonic
lethal abnormal vision (ELAV) family of proteins (43). It is expressed in a variety of cell
types and is detected in both the nucleus and cytoplasm. It is involved in insuring the
stabilization of many short-lived mRNA’s that contain AU (adenylate and uridylate) rich
elements (AREs). This process is key in the important steps involved in gene expression.
Post-transcriptional modification of mRNA can occur on many levels that involve the
processes of translocation, translation, editing, and degradation of the mRNA molecule.
This is particularly important in the context of the mRNA for a large number of
inflammatory cytokines including TNF-a, IL-6 and IL1"..

Many potential pathways have been explored to elucidate HuR shuttling. Studies
examining the role of AMPK in decreased HuR shuttling or increased HuR nuclear levels
show that AMPK activation serves as a unifying pathway in many potential inflammatory
or noxious cell stimuli including oxidative stress and hypoxia. However, studies of
various potential signaling pathways have yielded no direct regulatory answers. There has
been an important observation of the actions of importin-!, which is a key cytoplasmic
associated protein of HuR important in the importation of the protein into the nucleus.
Studies have shown that specific targeted activation of AMPK leads to modifications of
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importin-!, which increases its cytoplasmic levels and thus nuclear HuR levels (44).
Other observations have helped to shed light on potential pathways involved in the
regulation of HuR shuttling and its ability to stabilize mRNA (45).

Characterization of ApoE KO mouse model in study of Atherosclerosis
The ApoE deficient mouse model was developed to study the process of atherosclerosis
(46,47). The Maeda group provided the original mouse strain, which today is distributed
by Jackson Laboratory. Murine models have a number of caveats given the animal’s
relative differences in cholesterol physiology. At baseline, mice have high density
lipoprotein (HDL) levels as high as 85mg/dl (48). These mice do not develop
atherosclerotic plaques on regular chow diet and often require long intervals on a western
diet before the development of atherosclerotic lesions. This is possible because of the
expression of ApoE, which allows the mice to clear lipids efficiently. The ApoE
glycoprotein is synthesized in the liver, brain, monocytes and macrophages. With the
knockout of the ApoE gene, the mice develop atherosclerotic lesions on normal chow diet
and develop more significant lesions in shorter time frames on high fat diets. This allows
for study of atherosclerotic plaque development and other factors driving inflammation in
a more practical timeframe.

Despite the relative value of the ApoE deficient murine model there are several
shortcomings that raise the question as to whether or not findings in the model can be
completely extrapolated to humans (49). The first is the question of gender. Several
studies have shown that male and female murine models respond differentially to high fat
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diet. Tangirala et al have has shown that male models develop atherosclerotic lesions in
the aorta more frequently than models of the female gender at baseline (50). In addition,
their ApoE-/- model also displayed a trend towards higher incidence of atherosclerotic
plaque lesions in male mice compared to female mice but the difference was not
significant. After the study released by Tangirala there have been multiple studies that
have shown differences in incidence and size of atherosclerotic lesions in murine aorta
based on the timing in which the high fat diet is started and based on the gender of the
model. The gender differences have prompted questions into whether or not estrogen
plays a role in influencing the development of atherosclerotic plaque in the model.
Several studies performed in the ApoE-/- model have shown that manipulation of estrogen
levels leads to the same protective effects in the model. Elhage et al and Bourassa et al
have demonstrated that estrogen supplementation in ApoE -/- mice leads to inhibited fatty
streak development and reduced atherosclerotic lesion development respectively (49).
However, several studies have also shown that estrogen manipulation leads to nonprotective effects in the ApoE -/- model. A study utilizing tamoxifen, an estrogen
receptor agonist/antagonist based on tissue type, showed a regression of atherosclerotic
plaque in the ApoE -/- model (49).
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STATEMENT OF PURPOSE AND HYPOTHESIS
Cardiovascular disease is the leading cause of death in the United States (51). A majority
of cardiovascular disease stems from atherosclerotic coronary disease and HMG-CoA
reductase inhibitors have remained a standard of care in primary and secondary
prevention for the past quarter century. Our laboratory is interested in identifying novel
signaling pathways influenced by statins to develop new classes of therapeutics that
target inflammation and the immune system.

The hypothesis of this thesis is:
Isoprenylation is crucial to a signaling complex between Rac2 and Myosin IIA that
promotes the translocation of HuR from the nucleus to the cytosol.

The purpose of this thesis is to:
1. Demonstrate the importance of Rac2 and Myosin IIA in the translocation of
HuR
2. Demonstrate the role of "2 integrin adhesion in the formation of a signaling
complex between Rac2 and Myosin IIA in the setting of chemokine signaling.
3. Demonstrate the disruption of both the translocation of HuR and the complex
between Rac2 and Myosin IIA in the setting of atorvastatin treatment and reversal with
isoprenyl specific-rescue.
We believe that this pleotropic effect of statin may help to highlight this signaling
pathway as a potential target in the development of novel pharmacotherapeutics.
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METHODOLOGY
THP1 Cell Line
The human leukemic cell line (THP-1) was established using blood from a 1-year-old
boy with acute monocytic leukemia. These cells display several characteristics that define
its monocytic phenotype. Tsuchiya et al displayed that these cells phagocytized sheep
erythrocytes and 0.8 mm diameter latex particles (52). These cells also displayed the
ability to activate T-lymphocytes in the presence of Con A. In addition, these cells
display lysozyme production. Furthermore, these cells express a-naphthyl butyrate
esterase that is inhibited by NaF, which is an established distinguishing characteristic of
monocytic cells. These cells differentiate into a more macrophage like phenotype when
exposed to PMA. THP1 cells were cultured in RPMI supplemented media with FBS,
Pen/Strep/Glut with cell media replaced every 48-72 hours.
C57BL/6 & Rac2KO Bone Marrow Derived Macrophages
Bone marrow derived macrophages were isolated from the femurs and tibias of C57BL/6
and Rac2KO mice and placed in 10ml of fully supplemented RPMI media in a 50ml
conical tube. The fully supplemented RPMI media is 500ml RPMI, 2 µl 2-"ME, 5ml
HEPES, 5ml Pen/Strep, 5ml L. glutamine, 5ml sodium pyruvate, 50ml FBS. Remove
media and wash bones with 70% EtOH (3X). Remove EtOH and wash with 1X CMFPBS (3X). Grind bones in 10ml RPMI using mortar/pestle. Filter bone homogenate
through a 40µm strainer into a new 50ml conical tube. Add 10ml RPMI to mortar/pestle
and repeat homogenization/filter. Wash mortar/pestle with 10ml RPMI and filter this into
the same tube. Centrifuge at 1500 RPM for 5 minute at 4°C. Aspirate supernatant and resuspend pellet in 2ml lysis buffer. Add 3ml ACK lysis buffer and pipette up and down
with a glass Pasteur pipette (better yield). Incubate for 5 minute at RT. Add 10ml RPMI
to halt lysis. Centrifuge at 1500 RPM for 5 min at 4°C. Re-suspend pellet in 5ml 1X
CMF-PBS. Centrifuge at 1500 RPM for 5 min at 4°C. Obtain L cell media (-20°C). Resuspend pellet in 10ml L cell media + fully supplemented RPMI media and filter through
a 70µm strainer. Do cell counts. After cell counts, centrifuge media at 1500 RPM for 5
minute at 4°C. Re-suspend pellet L cell media + fully supplemented RPMI and plate 4~5
x106 cells in 7ml media in an Optilux petri dish (100x20mm). Cell counts and plate 4x106
cells in 7ml media in an Optilux petri dish (100x20mm). Add 4ml fresh, pre-warmed
macrophage media (L Cell) to each plate. Macrophages may be used on days 7-9, after
rinsing with 1xCMF-PBS, wash plates vigorously with 1x CMF-PBS containing 5mM
EDTA
Peripheral Blood Monocyte Extraction Assay
Peripheral Blood Monocytes were isolated from healthy human volunteers (53). Draw
blood from subject using heparinized collection tubes. Place blood into 50 ml conical
tube and dilute 50:50 with 1xPBS. Pellet leukocyte/RBC fraction by centrifugation of
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cells for 15 minutes at 200g at room temperature. Using sterile pipet add room
temperature 1xPBS to final volume of 40ml. Slowly layer Ficoll-Hypaque solution
underneath the leukocyte/RBC/PBS mixture by placing tip at bottom of tube (up to 10ml
or 3ml/10ml sample). Centrifuge 20-30 minutes in GH-3.7 rotor at 900g at 18°C no
brake. Using sterile pipet remove upper layer that contains plasma and most of cell
platelet function. Using another pipet transfer mononuclear lymphocyte cell layer to
another tube “white cloudy band”. Add HBSS and centrifuge 10 minutes at 450g.
Remove supernatant and re-suspend in HBSS. Re-suspend cells in complete RPMI-1640
and use for assays
Subcellular Fractionation Assay
Goal:
To biochemically determine Rac2 localization under non-stimulatory and stimulatory
events.
Reagents:
Thermo Scientific sub-cellular fractionation kit, 1xPBS, Cytoplasmic Extraction Buffer
(CEB), Membrane Extraction Buffer (MEB), Nuclear Extraction Buffer (NED),
Chromatin Extraction Buffer (NED), Cytoskeletal Extraction Buffer (PEB), Tabletop
micro-centrifuge
Method:
Prepare Buffer reagents according to recommendation of Thermo scientific subcellular
fractionation kit (78840). (500:500:250:250:250) ratio for CEB, MEB, NEB, NED, PEB
Buffers respectively. Our samples vary from 5x10^6 to 8x10^6 cells per sample so
approximate packed cell volume is 50%l. Add halt protease inhibitor cocktail in 1:100
ratio to each volume of buffer prior to use. Harvest cells. If suspension, spin cells down
in original media 1500rpm, 5 min, 25°C, remove media, then wash 1x with 1X PBS
(1500rpm, 5 min, 25°C). Remove PBS and add 500%l CEB Buffer. If adherent, remove
media with glass pipet. Wash with 10ml 1x PBS by swirling around plate. Remove PBS
and add 500-800%l CEB buffer directly to plate sample. Use cell scraper to dislodge
adherent cells, swirling buffer around plate in between successive cell scrapings. Place
sample on ice and use pipet to transfer buffer from plate to micro-centrifuge tube. Place
sample with CEB buffer in 4°C for 10 minutes with gentle rock. Remove sample from
4°C and micro-centrifuge for 5 minutes, 500g, 4°C. After centrifuge, transfer supernatant
to clean pre-chilled micro-centrifuge tube. Re-suspend pellet gently in 300%l of CEB
buffer and place in 4°C for 5 minutes with gentle rock (wash step). Centrifuge pellet for 5
minutes, 500g, 4°C and discard supernatant. Add 500 %l of MEB buffer to pellet and resuspend.Vortex on highest settling for 5 seconds. Place in 4°C with gentle rock for 10
minutes. Centrifuge sample 5 minutes, 3000g, 4°C. Remove supernatant and add to clean,
pre-chilled micro-centrifuge tube. Re-suspend pellet in 300%l of MEB buffer, vortex on
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highest setting for 3 seconds and place in 4°C for 5 minutes with gentle rock (wash step).
Centrifuge sample 5 minutes, 3000g, 4°C and discard supernatant. Re-suspend pellet in
250%l NEB buffer. Vortex on highest setting for 15 seconds. Place in 4°C and rock for 30
minutes. Centrifuge for 5 minutes, 5000g, 4°C. Transfer supernatant to clean pre-chilled
micro-centrifuge tube. Re-suspend pellet in 250%l NEB buffer with (5%l 100mM CaCl2
and 3%l Micrococcal Nuclease per 100%l of NEB).Vortex on highest setting for 15
seconds. Place in 37°C water bath for 5 minutes.Vortex on highest setting for 15 seconds.
Centrifuge at 5 minutes, 16000g, room temperature. Transfer supernatant to clean microcentrifuge tube. Re-suspend pellet in 100%l of NEB buffer with (5%l 100mM CaCl2 and
3%l Micrococcal Nuclease per 100%l of NEB).Vortex on highest setting for 15 seconds.
Discard supernatant. Add room temperature PEB Buffer and vortex on highest setting for
15 seconds. Incubate at room temperature for 10 minutes. Centrifuge for 5 min, 16000g
and transfer to new centrifuge tube. Save fraction on ice for same day use. For extended
storage freeze with liquid nitrogen and store in -80°C.
Immunofluorescence Assay
Goal:
Characterize association between Rac2, RhoGDI and LyGDI and localization of Rac2
under specific stimulatory conditions by immunofluorescence (54).
Reagents:
Rac2 antibody - (Santa Cruz) (polyclonal) (rabbit), RhoGDI antibody - (Santa Cruz)
(rabbit), LyGDI antibody - (Santa Cruz) (mouse and rabbit), Goat Serum IgG, Normal
IgG - rabbit (Santa Cruz), Normal IgG - mouse (Santa Cruz), 1x PBS .3% Triton, 1x
PBS, 4% Paraformaldehyde, 100% Methanol, 70% EtOH, 6 well glass tissue culture
treated plate, Glass coverslips (fisherbrand 22x22-1), Microscope slides (poly-lysine
treated), Styrofoam container with wells (leftover cuvette holder suffices), .01% w/v
poly-l-lysine (sigma)
Method:
Sterilize glass coverslips in 6 well plates with 1 of two methods. 1)Add EtOH to wells
and let sit for 15 minutes, then remove excess and let dry at room temp or overnight or 2)
First coat slides with poly-l-lysine, then UV irradiate overnight. Coat glass coverslips
with .01-w/v poly-l-lysine for 1 hour then remove excess. Allow glass slides to dry at
room temp or in 37 degree. Place cells in appropriate media and experimental condition
in each of the 6 well at 250,000 cell/ml density / 2ml total. Remove media from each of
the wells. Wash 1x with 1x PBS Sterile. Fix cells by adding 1ml 1xPBS 4%.
Paraformaldehyde and let sit for 15 minutes. Wash cells 3x with 1x PBS (5 min/wash).
Permeabilize cells with 100% Methanol (10 minutes @ -20°C). Wash cells 3x with 1x
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PBS (5min/wash). Block w/goat serum 5% by volume (50ul in 950 1xPBS, .3% triton) 1
hour at 4°C. Incubate in primary antibody (1 to 500 antibody to 1xPBS, .3% triton)
overnight. Wash cells 3x with 1x PBS (5 minutes/wash). Incubate cells with secondary
antibody (alexa-flour 488/568) for 2 hours. Wash cells 3x with 1x PBS (5 minutes/wash).
Stain cell nucleus with DAPI for 15-20 seconds. Wash cells 3x with 1x PBS. Mount cells
with Tris-Cl mounting solution and store in dark overnight. Visualize cells.
Rac GTPase Activation Assay
Goal: To determine activation state of Rac2 in biochemical assay across multiple
experimental conditions (55).
Reagents:
Rac2 antibody – Proteintech monoclonal, or C terminal class. THP1 cells 10x10^6 per
plate. PBD-Pak beads. Lysis Buffer:1ml HEPES, 7.5ml NACL (1M), 500ul triton X100,
5ml Glycerol, 400 %l EDTA, 400 %l EGTA, 35 ml h2o, protease inhibitor (1 tab per 10ml
per aliquot), GTP#S (non-hydrolyzable GTP), RPMI Media with FBS and Pen/Strep/Glut
Method:
Spin down at 1500rpm for 5 minutes at 25°C. Take off excess media. Lyse Cells in lysis
buffer 500%l (as per above). Allow cells to sit in lysis buffer on ice 5 minutes. Spin down
at 1000g 5minutes at 4°C. Take Supernatant do protein concentration. Take 50ug per
sample for TCL, re-suspend 4x buffer, boil, save -20°C. Take equal amount protein per
sample and add GTP#S (100%M – 5%l in 500%l solution) for 15 minutes at 37°C. During
this time re-suspend beads by flicking and place on ice. Add 12ul of beads to TCL from
GTP#S treatment to beads and rock at 4°C for 40 minutes. Spin down beads 400g 2
minutes, take off supernatant. Perform 2 washes of beads at 400g 2 minutes in lysis
buffer. Take beads and add to 40%l of 2x sample buffer (4x dissolved with H2O 2x
volume). Boil, run gel, transfer, Western blot for Rac2 and Myosin IIA
Immunoprecipitation Assay
Goal: Characterize association between any two desired proteins across multiple
experimental conditions (56).
Reagents:
Rac2 antibody - Santa Cruz (polyclonal) (rabbit), Rac2 antibody - Millipore (polyclonal)
(rabbit), Rho-GDI antibody - Santa Cruz (rabbit), Ly-GDI antibody - Santa Cruz (mouse
and rabbit), IP Buffer: 25mm Tris-Cl pH 7.4, 150mm NaCl, .1% Triton X-100, 2.5mm
EDTA, 1mm DTT, Protein A/G Beads
Method:
Add 4ug of IP antibodies to 40 %l of bead slurry in 500%l of PBS in 1.5 ml centrifuge
tube and rock in 4°C overnight. Lyse 10x10^6 cells in 1 ml IP buffer
Spin down samples at 9300g at 4°C for 10 minutes in microcentrifuge. Take supernatant.
Do protein concentration. Add 40%l of A/G bead slurry to each sample and rock in 4°C
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for 30 minutes (pre-clear). Spin down beads (6000 rpm, 6 minutes, 4°C) and take lysate.
After overnight A/G antibody incubation spin down beads (6000rpm, 6 minutes, 4°C).
Take off PBS supernatant. Add 500%g lysate to respective antibody samples. Rock
sample overnight at 4°C. Wash samples 2x with IP Buffer (6000 rpm, 6 minutes, 4°C).
Bring up in 40%l of sample buffer. Boil 4 minutes. Spin down beads at 10,000 rpm for 10
minutes and take sample buffer. Run 20%l per lane in small gel (4-15% gradient).
Western: Rac2, Rho-GDI, or Ly-GDI depending on experimental combination.
ICAM Localization Assay
Goal:
To utilize ICAM binding as signal for Rac2 activation across many different
experimental conditions.
Reagents:
Petri Dishes, 10%g/ml Goat Anti Human Igg-Fc in 50mM Tris-Cl pH 9.5 (100%l Anti
Human Igg for 10ml Tris-Cl), IgG, Tris-CL pH 9.5 *make 1M stock Tris base and pH
with HCL then filter sterilize, PBS-CMF, PBS + 2% dialyzed FBS 10ml in sterile 490 ml
PBS, rH ICAM 100ng/ml (-20°C ), rH Fc (-20°C), Assay Buffer: 20mM HEPES pH 7.4,
135 mM NaCl, 5mM KCL, 2mM Glucose, 1mM MgCl2, .6mM CaCl2, sterile filter. 4x
Lysis Buffer: 20mM HEPES pH 7.4, 150mM NaCl, 4% TritonX100, 40% Glycerol,
16mM EDTA, 16mM EGTA, 4 non EDTA protease inhibitor tablets
Method:
Coat plate with 5 %l of Igg Fc. Incubate at room temperature for 1 hour. Wash 2x with
PBS-CMF + 2% dialyzed FBS (simple swish and suction). Block by adding 5 ml PBS +
2% dialyzed FBS and let sit room temp for 1 hour. Take off PBS. Add 5 ml of rh ICAM
(100ng/ml in 2% dialyzed FBS / or 1 %l rh ICAM in 10ml dialyzed FBS) Swish around to
ensure even coating and put in 4°C overnight. If Fc plate use rh Fc (100ng/ml). Remove
media from rh ICAM or rh Fc coated plates. Take 10 million cells and separate out into
plates +/- PMA and incubate for 30 minutes. Prepare Assay buffer with PMA. 4ml assay
buffer. Dilute PMA 1 to 10 in DMSO and take 2 %l add to 4ml assay buffer). After 30
minute incubation wash cells 2x with PBS. Bring up in 1.2ml of assay buffer with PMA
per sample. Transfer to labeled ICAM plates and place in incubator for 60 minutes.
Gently remove assay buffer and add CEB buffer to each plate. Scrape plates and continue
with subcellular fractionation protocol
Cytochalasin D and Blebbistatin Inhibition Assay
Goal:
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To determine relationship of Rac2, actin and Myosin interaction.
Reagents:
Rac2 ab – Protein monoclonal, Myosin Antibody, THPI cells 10x10^6 per plate
Lysis Buffer:1ml HEPES, 7.5ml NACL (1M), 500ul triton X100, 5ml Glycerol, 400 %l
EDTA, 400 %l EGTA, 35 ml h2o, protease inhibitor (1 tab per 10ml per aliquot), MCP-1
(100ng/ml final concentration) (stock is 100ng/%l), Cytochalasin D (,01%m, .1%m, 1%m
and 10%m formulations) (5mg in 1ml stock), Blebbistatin (2%M, 10%M, 50%M
formulations), GTP#S, 10x10^6 cells per plate, RPMI Media with FBS and
Pen/Strep/Glut
Method:
Plate 10x10^6 THP1 cells per petri dish plate in 10ml media. Add 10%l MCP-1
(100ng/ml) to each plate. Let plate sit for 10 minutes. Spin down at 1500rpm for 5 minute
at 25°C. Take off excess media. Lyse Cells in lysis buffer 500%l (as per above). Allow
cells to sit in lysis buffer on ice 5 minutes. Spin down at 1000g 5minutes at 4°C. Take
Supernatant do protein concentration. Take 50%g per sample for TCL, re-suspend 4x
buffer, boil, save -20°C. Take equal amount protein per sample and add GTP#S (100uM
– 5ul in 500ul solution) for 15 minutes at 37°C. During this time re-suspend beads by
flicking and place on ice. Add 12ul of beads to TCL from GTP#S treatment to beads and
rock at 4°C for 40 minutes. Spin down beads 400g 2 minutes, take off supernatant.
Perform 2 washes of beads at 400g 2min in lysis buffer. Take beads and add to 40%l of 2x
sample buffer (4x dissolved with H2O 2x volume). Boil, run gel, transfer, Western blot
for Rac2 and myosin
Proximity Ligation Assay
Goal:
To characterize relationship between Rac2 and Myosin IIA.
Reagents:
Blocking Solution, Antibody Diluent, PLA probe (5x), Ligation Buffer (5x), Ligase
(1U/%l), Amplification (5x), Polymerase (10U/%l), Wash buffer A, Wash buffer B, Rac2
antibody, Myosin IIA antibody
Method:
Method adapted from DuoLink In Situ manual. Plate slides on cover slip and
permeabilize. Add blocking solution to each sample. Incubate the slides in pre-heated
chamber for 30 min at 37°C. Remove blocking solution from each sample. Add primary
antibody to each sample. Incubate antibody in humidity chamber (variable timing). Dilute
two PLA probes in 1:5 antibody diluent. Remove primary antibody from slides. Wash
slides in 1X buffer x2 5 minute each time. Add PLA probe solution. Incubate slides in
pre-heated humidity chamber for 1 hour at 37°C. Dilute ligation stock 1:5 in high purity
water and mix. Remove PLA probe from slides. Wash slides in 1x wash buffer A 2x at 5
minute with gentle agitation. Prepare ligase-ligation solution. Add ligase-ligation solution
to each sample. Incubate slides in preheated humidity chamber fro 30 minutes at 37°C.
Dilute amplification stock 1:5 in water and mix. Remove Ligase-ligation solution. Wash
1x with wash buffer A 2 minutes. Remove polymerase from freezer and prepare
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amplification-polymerase solution. Add amplification-polymerase solution to each
sample. Incubate slides in pre-heated humidity chamber for 100 minutes at 37°C.
Remove amplification-polymerase solution. Wash in 1x wash buffer B 2x for 10 minutes.
Wash in .01x wash buffer B fro 1 min. Let slides dry in dark at room temperature. Mount
slides
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RESULTS
Baseline Localization of Rac2
Prior studies have established a relationship between small GTPases like Rac2 and
RhoGDI (24). In figure 1, we utilize two protocols differing in wash conditions that
minimize contamination of protein fractions to accurately determine Rac 2 localization
under non-stimulatory conditions. Figure 1, vertical lane 2 shows a Rac2 signal in the
cytoplasmic fraction. Figure 1, vertical lane 4 shows no signal in the membrane fraction.
At baseline, Rac2 is localized to the cytosol. Figure 1, vertical lanes 2 and 4 also show a
signal for RhoGDI confirming its cytosolic predominance at baseline. We utilize
immunofluorescence to establish co-localization between Rac2 and RhoGDI in untreated
THP1 cells (Figure 2A). Consistent with earlier biochemical findings, the untreated
THP1 cells show an overlap pattern that has a high correlation coefficient of .916 (Figure
2B). The limitations to these findings include elevated nonspecific binding of IgG rabbit
antibody in control slides for immunofluorescence microscopy (Figure 3A, 3C). The IgG
rabbit is the same species as the Santa Cruz polyclonal Rac2 antibody utilized in the
assay. Interpretation of these results may be compromised by species pre-determined
non-specific binding and antibody quality. At the time of the experiment, the Rac2 rabbit
polyclonal was the best antibody available and was considered the standard for Rac2
detection. More data and exploration of the Rac2 RhoGDI association will need to be
done to fully understand the relationship between these proteins.

Effect of Atorvastatin on Rac2 localization
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Isoprenylation is an important post-translational modification that effects small GTPase
localization. To better characterize the effect of statin induced de-isoprenylation on Rac 2
localization, we treat THP1 cells with 10%m atorvastatin. Figure 4, vertical lane 3, row 1
shows that Rac2 localizes predominantly to the cytosol after 10%M atorvastatin treatment.
Vertical lane 6, row 1 shows that a small fraction of Rac2 can become membrane
associated after atorvastatin treatment. This is most likely explained by generalized
dysregulation due to loss of isoprenylation. The deregulated state allows a small but
detectable fraction of Rac2 to associate with the membrane. The western blot in figure 4
also shows a signal intensity difference between the untreated, PMA, PMA+atorvastatin
cytosolic lanes. As we discover later, this is due to the mechanism of antibody binding
for the directed class of antibody (Figure 5A, 6). At the time of the experiment, the Santa
Cruz antibody was considered the standard for Rac2 detection. The antibody is reacting
to the non-isoprenylated C-terminus of Rac2 and displays a variation in prenylation level.
The samples contain equal amounts of protein. The diminished signal of HSP90 is due to
statin effects on HSP90 expression. Samples are treated with GTP#S, which is a
nonhydrolyzable form of GTP that allows complete loading of Rac2 to promote the
activated state, before and after separation to determine protein fractions that could be
activated. In terms of the Rac2 relationship with Rho GDI after 10%M Atorvastatin
treatment, immunofluorescence microscopy shows a drop in the correlation coefficient to
.875 (Figure 2B). This is most likely representative of some disruption to the Rac2
RhoGDI interactions due to loss of isoprenylation. The same limitations to
immunofluorescence analysis apply as stated above and more work is needed to
characterize the statin effect.
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Effect of !2 integrin engagement and PMA on Rac2 activation
Rac2 activation is important to its cellular functions. Our experiments show that "2
integrin engagement with PMA co-stimulation causes Rac2 activation to levels detectable
by the activation assay (Figure 7). Figure 7 vertical lane 4 shows a detectable Rac2 signal
by pulldown with PBD-pak domain. Notably, in vertical lane 1 & 2, the Fc portion of
recombinant ICAM or PMA alone does not activate Rac2 to detectable levels. In vertical
lane 3, ICAM alone shows a very small level of Rac2 activation. Findings in Figure 7
suggest that integrin engagement requires stimulation to the high affinity states (with
PMA or other physiologic products) and thus the presence of integrin ligand alone is not
sufficient to load Rac2 to detectable levels for the Rac GTPase activation assay.
Mass spectrometry findings and Complex development
During the course of performing many of our pulldown assays we observed non-specific
antibody binding forming bands at roughly 40kDa and 200kDa. We provide a Coomassie
Blue stain that displays the pattern of these bands in relation to a PMA time-course
experiment (Figure 8). After mass spectrometry analysis, these bands were discovered to
be actin (coverage 78.7%) and non-muscle myosin IIA (coverage 61.5%) (Figure 9). This
result suggests that Rac2 activation in the setting of PMA could involve specific
cytoskeletal complexes necessary for creating an apparatus conducive for downstream
signaling.
Significance of isoprenylation in complex development
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THP1 cells with 0.1, 1, 10 and 100%M atorvastatin display concentration dependent loss
of complex formation in the setting of PMA and GTP#S (Figure 10). We observe loss of
actin and myosin IIA signal at atorvastatin concentrations & 10%M. This observation
correlates with an increase in signal intensity for Rac2 as shown in the pulldown row,
suggesting loss of prenylation as measured by Rac2 c-terminal class antibody (see below
for further detail). In addition, the Myosin IIA signal is lost at 10%M atorvastatin. These
results show that complex formation under the conditions of PMA + GTP#S is an
isoprenylation dependent process.
Complex formation is geranylgeranyl pyrophosphate dependent
We sought to recover complex formation by providing prenylation substrates
gernaylgeranylpyrophosphate (GGPP) and farnesylpyrophosphate (FPP) after coincubation of THP1 cells with 10%M Atorvastatin over 24 hours (Figure 11). In lane 1 of
figure 11, actin signal is at baseline while MyosinIIA signal is absent. In lane 2, complex
formation is demonstrated with increased actin and Myosin IIA signal in the context of
PMA stimulation. In lane 3, atorvastatin inhibits PMA induced complex formation as
there is a drop in signal for both actin and Myosin IIA. Complex recovery is suboptimal
in lane 4 with 5%M FPP, but near positive control levels with 5%M GGPP in lane 5 and
complete with 5%M GGPP+5%M FPP in lane 6. In addition, the isoprenylation state of
Rac2 is shown by western blot. Lanes 2 and 3 show loss of isoprenylation. Lanes 4 and 5
show recovery of isoprenylation with GGPP alone or GGPP+FPP. These results support
that the complex is dependent on isoprenylation substrate GGPP and that Rac2
isoprenylation is recovered with GGPP substrate.
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Complex formation is actin dependent
We demonstrate that complex formation is dependent on actin polymerization (Figure
12). THP1 cells were co-incubated with CCL2 and cytochalasin D. We inhibit actin
polymerization with .1, 1, and 10%M cytochalasin D and observe a dose dependent loss
of actin and Myosin IIA signal by western blot. This experimental result supports the
notion that formation of the complex is dependent on actin polymerization. In addition,
we utilize CCL2 in place of PMA to provide a more physiologic stimulatory signal.
Complex formation requires Myosin IIA
Further characterization of our complex was achieved with dose dependent inhibition of
Myosin IIA using Blebbistatin (Figure 13). Despite decreases in Myosin IIA signal by
western blot, actin levels remained stable. This shows that actin polymerization and
recruitment is independent of Myosin IIA recruitment to the signaling complex.
Demonstration of Complex existence in BMDM and human WBC
Complex formation is demonstrated in BMDMs under conditions of CCL2 coupled "2
integrin engagement (Figure 14). The significance of this figure is that the CCL2 coupled
"2 integrin engagement signal does not stimulate Rac1 or CDC42 association with
Myosin IIA suggesting specificity for the Rac2-Myosin IIA interaction. Further, complex
formation is inhibited in Rac2KO BMDM’s. To further demonstrate the existence of the
complex in human peripheral white blood cells, a screening assay was performed. Figure
14 shows formation of the complex under experimental conditions of PMA and GTP#S
loading in subjects not currently taking statins. However, for subjects taking statins
formation of the complex does not occur to the same extent. This screening figure gives
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some insight into the regulation of the complex in human cells and allows a first
molecular insight into pharmacologic statin therapy influencing this signaling complex.
More controls and further experiments are needed to expand on this concept.
Significance of Rac 2 Isoprenylation in Complex Formation
The significance of Rac2 isoprenylation is an important consideration in the formation of
the complex. A novel aspect to antibody binding was discovered when a new
monoclonal antibody became available for Rac2 (Figure 5A). The original Santa Cruz
and Abcam antibodies for Rac2 were polyclonal and recognized Rac2 by binding to the
C-terminus of the small GTPase. In states when Rac2 was isoprenylated by the GTases,
these antibodies appear to have more difficulty binding to the C-terminus of the small
GTPase and display a quantifiable decrease in signal. When Rac2 was non-isoprenylated
(in the case of statin treatment), these antibodies bind readily and reproducibly to the Cterminus. Around 2010-2011 antibodies were introduced to the market that recognized
full recombinant Rac2 (Proteintech) and bound to the protein regardless of prenylation
state. The differential binding provides a useful tool to access prenylation levels while
using full protein antibodies as loading controls as shown in (Figure 5B and 6).

Given this unique tool we were able to quantify the amount of time it takes for Rac2 loss
of isoprenylation to occur. As shown in figure 16A, we observe peak effect at 24 hours
with 10%M atorvastatin. By utilizing the Rac2 activation assay, we determined that nonisoprenylated Rac2 is able to achieve activation secondary to dysregulation of the GDI’s
ability to inhibit GTP loading. Our localization experiment hinted at the potential Rac2
activation when Rac2 localized to the membrane in that assay. In figure 16B, it is clear
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that non-isoprenylated Rac2 can become activated at higher concentrations than
isoprenylated Rac2 as shown by the activation assay. This raises questions as to whether
or not Rac2 fits in the general regulation model proposed for small GTPases.
HuR translocation is dependent on CCL2 coupled !2 integrin engagement and
inhibited by loss of prenylation
Prior to use of physiologic stimuli CCL2, we utilized PMA to activate cells. In prior
experiments, we have shown the ability of PMA coupled " integrin engagement to induce
HuR translocation to the cytoplasm and its dependence on isoprenylation (Figure 17).
Figure 17 row 1 shows no HuR translocation in untreated THP1 cells plated on poly-llysine. In overlay in lane 1, DAPI nuclear stain and HuR stain overlap. Row 2 shows that
PMA is insufficient to produce HuR translocation. Row 3 shows HuR translocation in
THP1 cells treated with PMA and plated on ICAM. Row 4 shows inhibition of HuR
translocation in THP1 cells treated with 10%M Atorvastatin, PMA and plated on ICAM.
With the use of physiologic stimuli, we demonstrate biochemically that CCL2 coupled "
integrin engagement and GGPP substrate are necessary for Rac2-Myosin IIA interaction
by pulldown assay in the context of 10%M atorvastatin treatment (Figure 18A). In row 1,
lane 1 and 2 there is no detectable pulldown of Myosin IIA in the presence of squalene or
no precursor. In row1, lane 3 there is a minor detectable amount of MyosinIIA in
pulldown with FPP as substrate. In row 1, lane 4, GGPP allows for a detectable
pulldown of Myosin IIA. In addition, there are no detectable amounts of isoprenylated
Rac2 with GGPP rescue. We also demonstrate by confocal analysis that HuR
translocation is dependent on CCL2 coupled " integrin engagement and isoprenylation
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(Figure 18B). With provision of prenylation substrate GGPP and GGPP+FPP, we are
able to rescue HuR translocation in the presence of atorvastatin.
Interactions between Rac2 and Myosin IIA
The "2integrin induced Rac2-myosin IIA interaction is unique to the literature and was
explored further in our experiments. Comparison of the activating signals of CCL2,
PMA+ICAM, ICAM and ICAM+CCL2 show that the Rac2-myosin IIA interaction is
achieved when dual signals from either CCL2 coupled "2 engagement or PMA coupled
"2 engagement is present (Figure 19). This further reinforces a multistep process as being
required for activation of Rac2. In order to discern if this interaction was even more
specific, experiments were conducted in knockout mice. Figure 14 shows the specificity
of this interaction in Rac2KO mice versus C57BL/6.

To further characterize the interactions between Rac2 and myosin IIA, a proximity
ligation assay (PLA) was utilized. Figure 20 shows the common stimulatory conditions,
Fc alone, CCL2+Fc, ICAM alone and CCL2+ICAM used and the resultant interactions
between Rac2 and MyosinIIA as measured by PLA. The signal is quantified by the red
emissions. In Figure 20 row 4 lane 2, we demonstrate that "2 integrin engagement and
CCL2 exposure promotes an interaction at a distance of 40nm between Rac2 and myosin
IIA as indicated by the strength of signal compared to other conditions.

In order to link chemokine coupled integrin engagement with HuR translocation in a
single display, quantify results and show potential clinical significance we utilized our
adhesion assay in a study of peripheral derived human monocytes (Figure 21). We plated
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the monocytes under stimulatory conditions as shown in (Figure 21). All exhibited some
spreading but there was a robust HuR response to CCL2 coupled "2 integrin engagement.
The translocation factors show appreciable differences and a large percentage of cells
under ICAM+CCL2 underwent HuR translocation compared to individual stimulators.

To further characterize the importance of Rac2 and myosin IIA in the precipitation of this
phenomenon we utilized Rac2KO and Myosin IIA KO BMDM. In figure 22, CCL2
coupled "2 integrin induced translocation of HuR is seen in the WT C57BL/6 mice but
not in the Rac2KO. Translocation factors are shown with percent cells with HuR
translocation. In our myosin knockout experiment, we utilize heterozygous myosin IIA
and myosin IIA KO mice to demonstrate that CCL2 coupled "2 integrin translocation is
not observed in the knockout. Quantification of HuR translocation factors and percentage
support these findings in figure 23.
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DISCUSSION
The dysregulation of small GTPases is an important consequence of statin therapy. It is
one of many pleiotropic effects that statins demonstrate in vitro and in vivo. Many studies
have been completed in an attempt to explain the clinical significance of small GTPase
dysregulation given the importance of these molecules in the function of macrophages.
The small GTPases hold a central position in the outside in signaling of "2 integrins.
These signaling cascades have been linked to monocyte/macrophage activation. Given
the centrality of macrophages in the inflammatory response to plaque formation and
progression, regulation of the small GTPase class of proteins takes on clinical
significance. Our aim was to explore the importance of Rac2 isoprenylation and the
significance the modification had on its localization and function.

Our results show that Rac2 is a dynamic protein whose regulation is dependent on
isoprenylation. Traditional models in the literature state that Rac2 is isoprenylated and
bound to GDI while in the cytosol (19). These models predict that an activation signal
causes members of the GTPase class to be dissociated from GDI and localize to the
membrane. Once at the membrane, the small GTPases can interact with exchange factors
that load it with GTP and allow for interaction with downstream effectors. While this
thesis does not readdress the Rac2 RhoGDI association in the literature, we do provide
immunofluorescent and western blot evidence that show Rac2 and RhoGDI in similar
subcellular fractions. Using a subcellular fractionation protocol we demonstrate that Rac2
can be localized to the membrane when provided the two signals consisting of PMA and
GTP#S. Further, our results confirm that Rac2 activation is a two-part phenomenon
&
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requiring integrin engagement and either PMA or CCL2 exposure. Using
immunoflourenscent staining, we show that statin pretreatment decreases the association
of RhoGDI with Rac2, again supporting this known relationship.

When Rac2 becomes activated through a coupled CCL2-"2 integrin activation signal, a
complex of proteins including Rac2, actin and myosin IIA are assembled. This complex
is conserved in THP1 monocytes, BMDM, and in an initial screening of human
peripheral blood monocytes. We demonstrate that formation of the complex is
isoprenylation dependent. This is a key finding that underlies the purpose of studying this
modification and this class of proteins. The dependency on isoprenylation is
demonstrated by specific substrate supplementation with GGPP and FPP, which allows
recovery of complex assembly after 10%M atorvastatin therapy. We are further able to
characterize the complex as dependent on actin polymerization and myosin IIA activation
because both cytochalasin D and blebbistatin inhibit complex formation.

The formation of the complex reorganizes the cytoskeleton and creates an environment
conducive for downstream signaling. We observe HuR translocation to the cytoplasm as
a significant event tied to CCL2 coupled "2 integrin activation of Rac2. HuR
translocation is significant because of its effects on stabilization of inflammatory and
angiogenic mRNA transcripts. As mentioned above, the Bender lab has shown
prolongation of message half-lives for transcripts that include TNF-!, IL-3, VEGF and
MMP-9 in an HuR dependent manner (35, 36, 37). Our experiments show consistent
linkage of CCL2 coupled "2-integrin Rac2 activation with HuR translocation through a
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variety of modalities. We also show the entire process to be isoprenylation dependent,
which directly links the effect of statin not only to complex formation but also the
propagation of inflammatory signals to HuR-mediated gene expression.

To further characterize the determinants of HuR translocation, cells from wild type,
Rac2KO, and Myosin IIA KO’s were utilized to discern the relative contributions of each
protein. Knockout experiments demonstrate both Rac2 and Myosin are critical to HuR
translocation. In fact, bone marrow-derived macrophages from their respective knock out
mice demonstrate phenotypic similarities in their diminished response to integrin
signaling. Given the novelty of the Rac2-myosin IIA interaction, we conducted
experiments to more closely study their relationship under CCL2 coupled "2-integrin
activation. Utilizing the Proximity Ligation Assay (PLA), we were able to quantify the
close relationship between Rac2 and Myosin IIA.

There remains more to explore in the mechanisms related to regulation of Rac2
prenylation. Our assays did not assess a time frame for cell dependent recovery of either
isoprenylation or protein turnover. Future experiments are needed to elucidate this story.

While our studies focused on a CCL2 coupled "2 integrin stimulation, more studies
should be carried out with other important chemokines such as CCL5 and CX3CL, which
are important in macrophage recruitment and activation in vitro and in vivo. Also,
experiments involving oxLDL assays should be completed to better characterize the
microenvironment of the plaque and study Rac2 specific signals.
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As more basic and clinical studies are completed, the relative contribution of the HuR
activation event and integrin mediated signaling pathway in the progression of
atherosclerotic plaques will be uncovered. HuR serves as a critical molecular switch in
gene expression with respect to the activation and differentiation of immune cells. The
above-described integrin-Rac-myosin axis appears to play a critical role in HuR
activation and serves as a pleiotropic target of statin therapy. Fully understanding the
mechanisms behind this pleotropic effect of statins has the potential to yield Rac2 and
myosin as potential targets for novel molecular therapeutics that modulate the immune
system.
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Figure 1: Baseline Rac2 and RhoGDI subcellular localization. THP1 cells were lysed
with separation of cytoplasmic and membrane fractions utilizing thermo scientific
subcellular fractionation buffers. Two separate subcellular fractionation protocols were
utilized for comparison. Western blot analysis performed with anti-Rac2 (C-terminus)
and anti-RhoGDI antibodies.
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Rac2
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Figure 2: Effect of atorvastatin on Rac2 RhoGDI interaction. A) THP1 cells were
adhered to poly-l-lysine coverslips, permeabilized, and immunoflourescent costaining
was performed with RhoGDI, Rac2, and DAPI for nuclear definition in untreated and
treated samples. Treated samples were incubated on poly-l-lysine coverslips in 10%M
atorvastatin for 24hrs at 37°C prior to permiabilization. Untreated samples were also
incubated overnight at 37°C B) Overlap coefficients from raw images were calculated
using ImageJ software version 1.43.
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Figure 3: Immunofluorescence characterization of controls. A) THP1 cells were
adhered to poly-l-lysine coverslips, permeabilized, and immunoflourescent costaining
was performed with IgG mouse and DAPI in row 1 and IgG rabbit and DAPI in row 2.
Images were overlaid and merges are noted. B) Using the same process applied in A,
THP1 cells underwent immunoflourescent costaining with anti-Na+/K+ ATPase and
DAPI for nuclear definition. C) C57BL/6 and Rac2KO BMDMs were adhered to poly-llysine coverslips, permeabilized and immunoflourescent costaining was performed with
anti-Rac2
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GTP!S after
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Rac2

GTP!S before
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Figure 4: Effect of Atorvastatin on Rac2 localization. THP1 cells subjected to the
indicated treatment conditions. PMA incubation lasts for 30 minutes and was performed
prior to cell lysis. Atorvastatin incubation lasted for 24 hours prior to lysis. Lysis was
performed with separation of cytoplasmic and membrane fractions using thermo
scientific subcellular fractionation buffers. Samples were incubated with 100%M GTP#S
for 15 minutes at 37°C before or after subcellular separation as indicated. Anti-Rac2 Cterminus antibodies were used for detection. Localization markers are provided for
cytoplasmic fraction (HSP90) and membrane fraction (Na/K ATPase).
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Fig. 1. Structures of the farnesyl-cysteine and gerarylgeranyl-cysteine.
T h e isoprenoid is attached via a thioether linkage from the C-l carbon
to the thiol of the amino acid.
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1732 the
Journal
of Lipid Researchmodification
Volume 33, 1992 targets. The Millipore antibody
the same location that
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was designed to recognize a recombinant form of the Rac2 protein. B). THP1, C57BL/6
and Rac2KO cells were incubated with 10%M atorvastatin for 24 hours. Samples were
then lysed, treated with 100%M GTP#S, and subjected to pulldown with PBD-pak beads
according to Rac GTPase activation assay. Anti-Rac2 antibodies to the C-terminus
(Abcam) and full recombinant (Proteintech) Rac2 protein were used for detection by
western blot.
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The increasing awareness that the presence of a CAAXmotif at its carboxyl terminus identified a protein as a
CPQPTROOcandidate for prenylation prompted a flurry of activity
directed toward determining the prenylation status of
such proteins. Searches of the protein sequence data bases
initially identified - 40 such candidates; surprisingly,
most of these proteinsSignal
were members of the class of G T P binding proteins (the so-called “small G proteins”) related
Antibody binds here

were also known to
be involved in cellular signaling events (1, 18). Essentially
all of these candidate proteins that have been closely inspected have been shown to be prenylated. To date, only
the 15-carbon farnesyl and 20-carbon geranylgeranyl
groups
have
been found
to modify proteins, with geranylFusion
Protein
residues
geranyl being the predominant isoprenoid attached (19,
1-192
20). Of considerable interest to those studying the enzymology of the prenylation processes (see below), the
COOH-terminal amino acid ( “ X ) of the CAAX box is
now known to specify which isoprenoid is attached to a
candidate protein. If this residue is a serine, methionine,
or glutamine residue, the protein contains the farnesyl
Signal
strong
a leucine at that position directs gerisoprenoid,
while
anylgeranyl addition (2, 21).
Prenylation is not the only posttranslational modification performed on proteins containing the CAAX-motif.
Specifically, the mature forms of these prenylated proteins
lack the three COOH-terminal amino acids (the “AAX).
A cellular peptidase (see Section VI) removes these three
amino acids, leaving the prenylated cysteine as the
COOH-terminal residue. Additionally, in all cases where
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Figure 6: Effect of Rac2 localization in BMDM. BMDM where isolated from femurs
and tibia of C57BL/6 mice. Cells where incubated in L-cell media + fully supplemented
RPMI for 7 days after which they were exposed to 10uM atorvastatin for 24hrs, lysed
utilized subcellular fraction protocol, and loaded into gel. Western blots were stained
with anti-Rac2 Abcam (c-terminus) and Millipore (full recombinant) antibodies.
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Figure 7: Effect of β2 integrin engagement and PMA on Rac2 activation. THP1 cells
were either incubated on Fc coated or ICAM coated plates for 60 minutes with PMA coincubation as indicated. GTP#S sample is provided as positive control. Cellular lysis and
pulldown with PBD-pak beads were performed according to Rac GTPase activation
assay. Aliquots were taken for total cell lysate (TCL). Anti-Rac2 C-terminus antibody or
anti-Rac1 antibody was used for protein detection by western blot in pulldown material
and total cell lysates as indicated.
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Figure 8: Effect of time dependent PMA incubation on complex formation. THP1
cells were incubated with PMA for 0, 1.5, 5 and 15 minutes as indicated. Cellular lysis
and pulldown were performed according to Rac GTPase activation assay. Samples were
run through 4-15% polyacrylamide gel at 200mV for 30minutes. Gel was then stained
with Coomassie brilliant blue for 1 hour and then destained with destaining solution.
Indicated bands on polyacrylamide labeled at roughly 40kDa and 200kDa were extracted
and sent for mass spectrometry analysis. Image developed on Licor system.
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Figure 1

Figure 9: Mass spectrometry results demonstrate actin and Myosin IIA. A) 41.7 kDa
band has 78.7% homology with actin. B) 226 kDa band has 61.5% coverage of nonmuscle Myosin IIA. These proteins are identified from Coomassie bands in (Figure 8).

In vertebrates, alternative splicing produces two MLCK
isoforms; MLCK-108 — best known as the conventional
smooth muscle MLCK — and MLCK-210, a high molecular weight isoform that consists of a carboxyl terminus
that is identical to MLCK-108 and a novel amino-terminal

phosphorylation of the RLC on Ser19: the Ca2+/calmodulin-dependent myosin light chain kinase (MLCK), Rho
kinase and p21-activated kinase [20–22].
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The biochemical properties of the two isoforms are also
consistent with the premise that myosin-IIA and myosinIIB are functionally distinct. Myosin-IIA has a maximal
actin-activated ATPase activity that is 2.6-fold greater
than that of myosin-IIB, and moves actin filaments at
velocities 3.3-fold faster than those observed with myosinIIB [15]. The identification of a single isoform in some
cell types suggests that in certain contexts myosin-IIA and
myosin-IIB may be functionally interchangeable; howev-

LVWVPSDKSG
SKVEDMAELT
SEEIVEMYKG
TENTKKVIQY
NSSRFGKFIR
LSGAGEHLKT
IPEEEQMGLL
NVTDFTRGIL
LRINKALDKT
NHTMFILEQE
ECWFPKATDK
ADEWLMKNMD
ALPGAFKTRK
GKLDPHLVLD
KGFMDGKQAC
DVIIGFQACC
FTKVKPLLQV
EKLQLQEQLQ
CQHLQAEKKK
IILEDQNCKL
DLEERLRREE
KEEELQAALA
EKQKRDLGEE
KTHEAQIQEM
NEVKVLLQGK
ELDNVTGLLS
LKQVEDEKNS
ETAEEVKRKL
HQRQSACNLE
LARALEEAME
EQQVEEMKTQ
EEKKKQLVRQ
KNRDEAIKQL
EMIQLQEELA
IAQLEEELEE
QQLERQNKEL
QAACKQVRRT
EAEEEAQRAN
PRRMARKGAG

Current Opinion in Cell Biology

LAQADWAAKK
DIQKMNPPKF
INPYKNLPIY
LCTGESGAGK
FGNAKTVKND
ERTFHIFYYL
ETMEAMRIMG
AQKVSHLLGI
TYERMFRWLV
YTNEKLQQLF
PPGILALLDE
IHYAGKVDYK
LDQVAGMSET
CIIPNHEKKA
YEILTPNSIP
LEEERDLKIT
KLRNWQWWRL
METLQSQLMA
EARVEEEEER
AKLKKLEEEQ
LKNKHEAMIT
IAELKMQLAK
ESERASRNKA
ILKKTLEEEA
TLENERGELA
LADKVTKLQV
NRQKLSLSTK
KKMEDSVGCL
ELDDLLVDLD
AREKETKALS
HELEKSKRAL
RDLQGRDEQS
DLEAHIDSAN
NEKKLKSMEA
LEEKRRLEAR
SHAQKNENAR
EQLDNETKER
RLKQLKRQLE
LRRGDLPFVV

Schematic diagram of nonmuscle myosin-II.
Myosin-II is a hexamer composed of two
heavy chains, two essential light chains (black)
and two regulatory light chains (gray). Each
heavy chain is composed of a globular aminoterminal head containing the ATP and actin
binding domains required for motor activity, an
intermediate domain that dimerizes to form an
!-helical coiled coil and a carboxy-terminal
nonhelical tailpiece.
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Figure 10: Effect of atorvastatin complex formation. THP1 cells were incubated with
0.1, 1, 10 and 100%M of atorvastatin over 24 hour period. Samples were treated with
100%M GTP#S for 15mins at 37°C, lysed and subjected to pulldown with PBD-pak
beads. Aliquots were set aside for total cell lysates (TCL). Two polyacrylamide gels were
run at 200mV for 30 mins. Gel 1 was stained with Coomassie brilliant blue for 1 hour and
then destained with destaining solution. Image developed on Licor System. Gel 2 was
transferred to western and stained with anti-Rac2 C-terminus antibody and anti-actin as
indicated.
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Figure 11: Effect of GGPP and FPP supplementation on Atorvastatin mediated
complex inhibition. THP1 cells were incubated with 10%M atorvastatin for 24 hours and
provided no substrate, 5%M FPP, 5%M GGPP or 5%M FPP + 5%M GGPP as indicated.
Negative control without statin therapy or PMA is provided. Positive control with PMA
is provided. Samples were lysed and separated aliquots for pulldown and total cell
lysates. Pulldown samples were treated with 100%M GTP#S for 15mins at 37°C, and
subjected to PBD-pak beads. Aliquots were set aside for total cell lysates (TCL). Two
polyacrylamide gels were run at 200mV for 30 mins. Gel 1 was stained with Coomassie
brilliant blue for 1 hour and then destained with destaining solution. Image of gel
developed on Licor system. Gel 2 was transferred to western and stained with anti-Rac2
and anti-actin as indicated.
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Figure 12: Effect of Cytochalasin D on complex formation. THP1 cells were incubated
with 0.1, 1, and 10%M cytochalasin D and 100ng/mL of CCL2 as indicated. Negative
control without CCL2 or Cytochalasin D is provided. Positive control with CCL2 is
provided. Samples were lysed, treated with 100%M GTP#S for 15mins at 37°C, and
subjected to pulldown with PBD-pak beads according to Rac GTPase activation assay.
Anti-Rac2 antibodies (full recombinant), anti-actin, and anti-Myosin IIA antibodies were
used for detection by western blot.
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Figure 13: Effect of Blebbistatin on complex formation. THP1 cells were incubated
with 2,10, and 50%M blebbistatin as indicated. Negative control is provided with no
PMA. Positive control is provided with PMA. Samples were lysed, treated with 100%M
GTP#S for 15mins at 37°C performed according to Rac GTPase activation assay.
Samples were run through 4-15% polyacrylamide gel at 200mV for 30mins. Gel was then
stained with Coomassie brilliant blue for 1 hour and then destained with destaining
solution. Image was developed on Licor System.
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Figure 14: Knockdown of Rac2 Myosin IIA interaction in Rac2KO BMDMs. BMDM
from C56BL/6 and Rac2KO are exposed to CCL2. Samples were lysed, treated with
100uM GTP#S for 15mins at 37°C, and subjected to pulldown with PBD-pak beads
according to Rac GTPase activation assay. Anti-Rac2 (full recombinant), anti-Rac1, and
anti-CDC42 antibodies were used to detect respective proteins by western blot. Total cell
lysates (TCL) are provided.
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Figure 15: Effect of PMA and history of current statin use on complex formation in
human derived peripheral WBC’s. Human monocytes were isolated from whole blood
in heparinized tubes from 4 volunteers who varied by gender and statin usage. Whole
blood was fractionated by centrifugation for 30 minutes at 900g. Mononuclear
lymphocyte cell layer was isolated, added to HBSS solution and re-suspended in RPMI1640. Cells were then stimulated with PMA for 30 minutes, lysed, treated with 100%M
GTP#S for 15 minutes at 37°C, denatured in sample buffer and run through 4-15%
polyacrylamide gel at 200mV for 30 minutes. Gel was then stained with Coomassie
brilliant blue for 1 hour and then destained with destaining solution. Image was
developed on Licor System.
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Figure 16: Characterization of time to loss of isoprenylation with Atorvastatin. A)
THP1 cells were incubated with 10%M Atorvastatin for 0, 1.5, 3, 6, 12, 24 and 48 hours.
The first sample group was lysed, subjected to pulldown with PBD-pak beads according
to Rac GTPase activation assay. The second sample group was lysed, treated with 100%M
GTP#S for 15mins at 37°C, and subjected to pulldown with PBD-pak beads according to
Rac GTPase activation assay. Anti-Rac2 antibodies to the c-terminal (Abcam) and full
(Millipore) recombinant Rac2 protein were used for detection by western blot as
indicated. B) Quantification of ratio of pulldown +/- GTP#S to loading control is
provided.
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Figure 17: Effect of Atorvastatin on β2 integrin engagement and PMA induced
HuR translocation. THP1 cells were adhered to either poly-l-lysine or ICAM coated
coverslips and incubated in PMA or Atorvastatin 10%M for 24 hours as indicated. These
cells were then permeabilized, and immunoflourescent costaining was performed with
anti-HuR and DAPI for nuclear definition.
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Figure 18: Effect of Rac2 isoprenylation state on Rac2-Myosin IIA interaction and
subsequent HuR translocation. A) THP1 cells were incubated with 10%M Atorvastatin
for 24 hours and were terminally incubated with CCL2 for 15 minutes. Samples were
provided no precursor, squalene, FPP, or GGPP over the 24 hours prior to lysis as
indicated. Samples were lysed, treated with 100%M GTP#S for 15 minutes at 37°C and
subjected to pulldown with PBD-pak beads according to Rac GTPase activation assay. B)
Samples with same treatment from conditions if figure A were fixed and stained for
confocal analysis. Anti-HuR, anti-actin and DAPI staining for nuclear definition are
utilized.
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Figure 19: Effect of β2 integrin engagement and CCL2 on Rac2 interaction with
Myosin IIA. Human monocyte cells are incubated with PMA and 100mg/mL of MCP1
for 15 minutes. Samples were lysed and subjected to pulldown with PBD-pak beads
according to Rac GTPase activation assay. Anti-Rac2 (full recombinant) and anti-Myosin
IIA antibodies were used to detect Rac2 and Myosin IIA by western blot.
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Figure 20: Characterization of CCL2 coupled B2 integrin engagement on Rac2
Myosin IIA interaction as determined by proximity ligation assay. Samples are
subjected to CCL2 alone, ICAM alone and CCL2+ICAM as indicated. Cells were fixed
to coverslips, permeabilized, and stained with anti-Rac2 (full recombinant) and antiMyosin IIA. A PLA probe was then utilized in conjunction with a ligation-ligase solution
to hybridize the two PLA probes in close proximity. An amplification solution containing
fluorescently labeled oligonucleotides was provided with polymerase allowing the
creation of a rolling circle amplification product signal detected by microscopy.
Individual images were overlaid and merges displayed as indicated.
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Figure 21: Effect of CCL2 coupled β2 Integrin engagement on HuR translocation.
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Figure 22: Significance of Rac2 in Chemokine-coupled !2 Integrin-induced HuR
Translocation. A) BMDM isolated from C57BL/6 and RAC2KO are subjected to
CCL2+ICAM. B) Quantitative analysis of HuR translocation by translocation factor and
translocation percentage are provided.
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Figure 23: Significance of Myosin IIA in Chemokine-coupled !2 Integrin-induced
HuR Translocation. A) BMDM from myosin knockout and heterozygous mice are
subjected to ICAM+CCL2 or CCL2 alone stimulation. Samples are stained with DAPI,
HuR, and actin and subfigures are merged. B) Quantitative analysis of HuR translocation
by translocation factor and translocation percentage for each experimental condition are
provided.
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